CR8794A - Adenovirus quimericos para uso en el tratamiento del cancer - Google Patents

Adenovirus quimericos para uso en el tratamiento del cancer

Info

Publication number
CR8794A
CR8794A CR8794A CR8794A CR8794A CR 8794 A CR8794 A CR 8794A CR 8794 A CR8794 A CR 8794A CR 8794 A CR8794 A CR 8794A CR 8794 A CR8794 A CR 8794A
Authority
CR
Costa Rica
Prior art keywords
adenovirus
chemicals
cancer
treatment
adenoviruses
Prior art date
Application number
CR8794A
Other languages
English (en)
Inventor
Paul Harden
Terry Hermiston
Irene Kuhn
Original Assignee
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Shering Pharma Ag filed Critical Bayer Shering Pharma Ag
Publication of CR8794A publication Critical patent/CR8794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a adenovirus oncoliticos con aplicaciones terapeuticas. Se proveen adenovirus quimericos recombinantes y metodos para producirlos. Los adenovirus quimericos de la invencion comprenden secuencias de acido nucleico derivadas de los serotipos adenovirales clasificados en los subgrupos B a F y presentan un indice terapeutico mejorado.
CR8794A 2004-05-26 2006-12-06 Adenovirus quimericos para uso en el tratamiento del cancer CR8794A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57485104P 2004-05-26 2004-05-26

Publications (1)

Publication Number Publication Date
CR8794A true CR8794A (es) 2007-08-28

Family

ID=35355425

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8794A CR8794A (es) 2004-05-26 2006-12-06 Adenovirus quimericos para uso en el tratamiento del cancer

Country Status (32)

Country Link
US (6) US7510868B2 (es)
EP (1) EP1749098B1 (es)
JP (1) JP4787936B2 (es)
KR (1) KR101169109B1 (es)
CN (3) CN104263703B9 (es)
AR (2) AR049188A1 (es)
AT (1) ATE491799T1 (es)
AU (1) AU2005250396B2 (es)
BR (2) BRPI0510475B8 (es)
CA (2) CA2567094C (es)
CR (1) CR8794A (es)
DE (1) DE602005025340D1 (es)
DK (1) DK1749098T3 (es)
EC (1) ECSP067088A (es)
ES (1) ES2358204T3 (es)
GT (1) GT200500129A (es)
HR (1) HRP20110179T1 (es)
IL (2) IL179098A (es)
MX (1) MXPA06013570A (es)
MY (1) MY140829A (es)
NO (1) NO340708B1 (es)
NZ (1) NZ551443A (es)
PA (1) PA8634201A1 (es)
PE (1) PE20060277A1 (es)
PL (1) PL1749098T3 (es)
PT (1) PT1749098E (es)
RU (1) RU2448157C2 (es)
TW (1) TWI366603B (es)
UA (1) UA89957C2 (es)
UY (1) UY28926A1 (es)
WO (1) WO2005118825A2 (es)
ZA (1) ZA200610763B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE491799T1 (de) 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
US20070258952A1 (en) * 2006-05-04 2007-11-08 Baylor Research Institute Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
WO2008060510A2 (en) 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
EP2094284A2 (en) * 2006-12-22 2009-09-02 Bayer Schering Pharma AG Generation of oncolytic adenoviruses and uses thereof
KR100856310B1 (ko) 2007-02-28 2008-09-03 삼성전기주식회사 이동통신 단말기
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
AP2014007994A0 (en) * 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
SG11201506624SA (en) 2013-02-28 2015-09-29 Psioxus Therapuetics Ltd A process for the production of adenovirus
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
SG11201510064WA (en) * 2013-06-14 2016-01-28 Psioxus Theraupeutics Ltd A dosing regime and formulations for type b adenoviruses
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
SI3021859T1 (en) * 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
GB2531821A (en) * 2013-10-25 2016-05-04 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201415579D0 (en) 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
KR20170044194A (ko) 2014-08-27 2017-04-24 싸이오서스 테라퓨틱스 엘티디. 아데노바이러스의 제조를 위한 공정
DK3198009T3 (da) 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder
JP6931229B2 (ja) * 2015-04-30 2021-09-01 サイオクサス セラピューティクス リミテッド Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
DK3389682T3 (da) 2015-12-17 2022-01-24 Psioxus Therapeutics Ltd Gruppe b-adenovirus, der koder for et anti-tcr-kompleks-antistof eller -fragment
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
US11273170B2 (en) * 2016-07-25 2022-03-15 Ascend Biopharmaceuticals Ltd Methods of treating cancer
WO2018041827A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
SMT202300252T1 (it) 2017-06-01 2023-09-06 Akamis Bio Ltd Virus oncolitico e metodo
CA3074291A1 (en) 2017-09-05 2019-03-14 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US12295976B2 (en) 2018-03-28 2025-05-13 Epicentrx, Inc. Personalized cancer vaccines
CA3096099A1 (en) 2018-04-09 2019-10-17 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
EP4219527A3 (en) 2018-11-21 2023-08-09 Mayo Foundation for Medical Education and Research Adenoviruses and methods for using adenoviruses
IL292788B2 (en) 2019-04-29 2023-12-01 Mayo Found Medical Education & Res Multivalent pd-l1 binding compounds for treating cancer
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
GB202009701D0 (en) * 2020-06-25 2020-08-12 Theolytics Ltd Generation of diverse viral libraries
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
NZ269156A (en) 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) * 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
ES2231103T5 (es) * 1999-05-17 2010-04-15 Crucell Holland B.V. Vehiculos de transferencia de genes derivados de adenovirus que comprenden al menos un elemento de adenovirus tipo 35.
EP1083228A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
JP2003534806A (ja) * 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
ATE449859T1 (de) * 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
AU2003223775A1 (en) * 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
ATE491799T1 (de) 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
EP2094284A2 (en) 2006-12-22 2009-09-02 Bayer Schering Pharma AG Generation of oncolytic adenoviruses and uses thereof

Also Published As

Publication number Publication date
HRP20110179T1 (hr) 2011-04-30
CA2836987C (en) 2016-07-05
US20090227000A1 (en) 2009-09-10
PL1749098T3 (pl) 2011-05-31
DK1749098T3 (da) 2011-04-04
EP1749098A2 (en) 2007-02-07
US20120231524A1 (en) 2012-09-13
GT200500129A (es) 2006-03-23
CN102816742A (zh) 2012-12-12
CN102816742B (zh) 2014-04-09
BRPI0510475B8 (pt) 2021-05-25
US8158599B2 (en) 2012-04-17
US20150037874A1 (en) 2015-02-05
HK1179655A1 (en) 2013-10-04
US9234185B2 (en) 2016-01-12
MXPA06013570A (es) 2007-02-08
US20130217095A1 (en) 2013-08-22
CN104263703A (zh) 2015-01-07
US20130209409A1 (en) 2013-08-15
CN104263703B (zh) 2018-01-09
CA2567094C (en) 2014-11-25
CN1997746A (zh) 2007-07-11
NO340708B1 (no) 2017-06-06
ZA200610763B (en) 2009-06-24
PE20060277A1 (es) 2006-05-25
UY28926A1 (es) 2006-01-31
CN104263703B9 (zh) 2019-12-17
JP4787936B2 (ja) 2011-10-05
CN1997746B (zh) 2012-09-26
CA2836987A1 (en) 2005-12-15
IL179098A0 (en) 2007-03-08
WO2005118825A3 (en) 2006-11-23
TWI366603B (en) 2012-06-21
HK1205529A1 (en) 2015-12-18
TW200611974A (en) 2006-04-16
RU2006145071A (ru) 2008-07-10
DE602005025340D1 (de) 2011-01-27
ECSP067088A (es) 2007-01-26
HK1109421A1 (en) 2008-06-06
ES2358204T3 (es) 2011-05-06
WO2005118825A2 (en) 2005-12-15
US20050265973A1 (en) 2005-12-01
NZ551443A (en) 2010-01-29
UA89957C2 (ru) 2010-03-25
IL226820A (en) 2017-07-31
CA2567094A1 (en) 2005-12-15
ATE491799T1 (de) 2011-01-15
PA8634201A1 (es) 2006-11-09
PT1749098E (pt) 2011-02-02
KR20070020302A (ko) 2007-02-20
AR090647A2 (es) 2014-11-26
IL226820A0 (en) 2013-07-31
BRPI0510475B1 (pt) 2020-09-29
IL179098A (en) 2015-09-24
AU2005250396A1 (en) 2005-12-15
US20130230902A2 (en) 2013-09-05
US9034344B2 (en) 2015-05-19
NO20066002L (no) 2006-12-22
US8765463B2 (en) 2014-07-01
BRPI0510475A (pt) 2007-11-06
BR122013008865B1 (pt) 2020-11-24
BR122013008865B8 (pt) 2021-05-25
US7510868B2 (en) 2009-03-31
JP2008500051A (ja) 2008-01-10
MY140829A (en) 2010-01-29
AR049188A1 (es) 2006-07-05
RU2448157C2 (ru) 2012-04-20
US9115337B2 (en) 2015-08-25
KR101169109B1 (ko) 2012-07-26
EP1749098B1 (en) 2010-12-15
AU2005250396B2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
CR8794A (es) Adenovirus quimericos para uso en el tratamiento del cancer
NZ628213A (en) Adenoviruses expressing heterologous tumor-associated antigens
DOP2013000111A (es) Anticuerpos neutralizadores anti-ccl20
ECSP10010288A (es) Vectores de virus oncolíticos de viruela
BR112019024813A2 (pt) adenovírus recombinantes portando transgenes
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
MX373835B (es) Adenovirus oncolíticos armados con genes heterólogos.
MX2022011180A (es) Interruptores transcripcionales activados mediante union y metodos para su uso.
EA201791971A1 (ru) Онколитический аденовирус, кодирующий белок b7
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
ECSP10010287A (es) Vectores de virus oncolíticos de viruela
AR090318A1 (es) Lotes de adenovirus recombinantes con extremos terminales alterados
BRPI0418805B8 (pt) construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
WO2019227106A9 (en) Tumor-specific neoantigens and methods of using the same
EA201890274A1 (ru) Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы
PL1771468T3 (pl) Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL)
MX348430B (es) Proteinas derivadas de genes cry de bacillus thuringiensis.
CO6571869A2 (es) Péptidos ect2 y vacunas que los incluyen
BR112022008726A2 (pt) Vetor adenovírus recombinante com replicação viral melhorada, tipo celular específico e método de tratamento de uma malignidade
Pol et al. Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses
MX2024005404A (es) Vacunas de cancer dirigidas a lemd1 y sus usos.
EA201890595A1 (ru) Онколитический аденовирус, кодирующий белок b7
MX2014010873A (es) Lotes de adenovirus recombinantes con extremos alterados.